vs
Side-by-side financial comparison of BLACKLINE, INC. (BL) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
BLACKLINE, INC. is the larger business by last-quarter revenue ($183.2M vs $177.4M, roughly 1.0× Pacira BioSciences, Inc.). BLACKLINE, INC. runs the higher net margin — 2.7% vs 1.6%, a 1.0% gap on every dollar of revenue. On growth, BLACKLINE, INC. posted the faster year-over-year revenue change (8.1% vs 5.0%). Over the past eight quarters, BLACKLINE, INC.'s revenue compounded faster (7.9% CAGR vs -0.2%).
BlackLine Systems, Inc., is an American enterprise software company that develops cloud-based services designed to automate and manage the entire financial close process as well as consolidation, invoice-to-cash, and intercompany accounting. The Los Angeles–based company has 17 offices worldwide.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
BL vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.2M | $177.4M |
| Net Profit | $4.9M | $2.9M |
| Gross Margin | 75.2% | — |
| Operating Margin | 3.7% | 3.9% |
| Net Margin | 2.7% | 1.6% |
| Revenue YoY | 8.1% | 5.0% |
| Net Profit YoY | -91.3% | — |
| EPS (diluted) | $0.07 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $183.2M | $196.9M | ||
| Q3 25 | $178.3M | $179.5M | ||
| Q2 25 | $172.0M | $181.1M | ||
| Q1 25 | $166.9M | $168.9M | ||
| Q4 24 | $169.5M | $187.3M | ||
| Q3 24 | $165.9M | $168.6M | ||
| Q2 24 | $160.5M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $4.9M | — | ||
| Q3 25 | $5.3M | $5.4M | ||
| Q2 25 | $8.3M | $-4.8M | ||
| Q1 25 | $6.1M | $4.8M | ||
| Q4 24 | $56.4M | — | ||
| Q3 24 | $17.2M | $-143.5M | ||
| Q2 24 | $76.7M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 75.2% | 79.5% | ||
| Q3 25 | 75.1% | 80.9% | ||
| Q2 25 | 75.2% | 77.4% | ||
| Q1 25 | 75.5% | 79.7% | ||
| Q4 24 | 75.6% | 78.7% | ||
| Q3 24 | 75.2% | 76.9% | ||
| Q2 24 | 74.9% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 3.7% | 1.2% | ||
| Q3 25 | 4.3% | 3.5% | ||
| Q2 25 | 4.4% | 4.7% | ||
| Q1 25 | 2.1% | 1.2% | ||
| Q4 24 | 3.7% | 13.2% | ||
| Q3 24 | 5.0% | -82.8% | ||
| Q2 24 | 1.4% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 2.7% | — | ||
| Q3 25 | 3.0% | 3.0% | ||
| Q2 25 | 4.8% | -2.7% | ||
| Q1 25 | 3.6% | 2.8% | ||
| Q4 24 | 33.3% | — | ||
| Q3 24 | 10.4% | -85.1% | ||
| Q2 24 | 47.8% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.07 | $0.05 | ||
| Q3 25 | $0.09 | $0.12 | ||
| Q2 25 | $0.13 | $-0.11 | ||
| Q1 25 | $0.10 | $0.10 | ||
| Q4 24 | $0.79 | $0.38 | ||
| Q3 24 | $0.27 | $-3.11 | ||
| Q2 24 | $0.22 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $390.0M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $332.3M | $653.9M |
| Total Assets | $1.8B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $390.0M | $238.4M | ||
| Q3 25 | $419.9M | $246.3M | ||
| Q2 25 | $459.1M | $445.9M | ||
| Q1 25 | $479.5M | $493.6M | ||
| Q4 24 | $885.9M | $484.6M | ||
| Q3 24 | $725.3M | $453.8M | ||
| Q2 24 | $616.6M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $332.3M | $693.1M | ||
| Q3 25 | $328.3M | $727.2M | ||
| Q2 25 | $414.0M | $757.8M | ||
| Q1 25 | $417.9M | $798.5M | ||
| Q4 24 | $446.7M | $778.3M | ||
| Q3 24 | $367.9M | $749.6M | ||
| Q2 24 | $325.8M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.8B | $1.3B | ||
| Q3 25 | $1.7B | $1.3B | ||
| Q2 25 | $1.8B | $1.5B | ||
| Q1 25 | $1.8B | $1.6B | ||
| Q4 24 | $1.8B | $1.6B | ||
| Q3 24 | $1.7B | $1.5B | ||
| Q2 24 | $1.9B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $26.7M | — |
| Free Cash FlowOCF − Capex | $26.1M | — |
| FCF MarginFCF / Revenue | 14.2% | — |
| Capex IntensityCapex / Revenue | 0.3% | — |
| Cash ConversionOCF / Net Profit | 5.46× | — |
| TTM Free Cash FlowTrailing 4 quarters | $161.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $26.7M | $43.7M | ||
| Q3 25 | $63.8M | $60.8M | ||
| Q2 25 | $32.3M | $12.0M | ||
| Q1 25 | $46.7M | $35.5M | ||
| Q4 24 | $43.8M | $33.1M | ||
| Q3 24 | $55.9M | $53.9M | ||
| Q2 24 | $40.7M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $26.1M | $43.5M | ||
| Q3 25 | $63.3M | $57.0M | ||
| Q2 25 | $31.4M | $9.3M | ||
| Q1 25 | $40.8M | $26.9M | ||
| Q4 24 | $43.0M | $31.0M | ||
| Q3 24 | $55.5M | $49.8M | ||
| Q2 24 | $40.0M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 14.2% | 22.1% | ||
| Q3 25 | 35.5% | 31.7% | ||
| Q2 25 | 18.2% | 5.1% | ||
| Q1 25 | 24.4% | 15.9% | ||
| Q4 24 | 25.4% | 16.6% | ||
| Q3 24 | 33.5% | 29.6% | ||
| Q2 24 | 24.9% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.3% | 0.1% | ||
| Q3 25 | 0.3% | 2.2% | ||
| Q2 25 | 0.6% | 1.5% | ||
| Q1 25 | 3.6% | 5.1% | ||
| Q4 24 | 0.4% | 1.1% | ||
| Q3 24 | 0.2% | 2.4% | ||
| Q2 24 | 0.4% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 5.46× | — | ||
| Q3 25 | 12.07× | 11.20× | ||
| Q2 25 | 3.90× | — | ||
| Q1 25 | 7.72× | 7.37× | ||
| Q4 24 | 0.78× | — | ||
| Q3 24 | 3.24× | — | ||
| Q2 24 | 0.53× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BL
| Subscription And Circulation | $173.2M | 95% |
| Technology Service | $10.0M | 5% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
